Accueil > Actualité
Actualite financiere : Actualite bourse

AstraZeneca: positive results in breast cancer

(CercleFinance.com) - On Monday AstraZeneca announced that Enhertu, the antibody-conjugate that it is developing with Japan's Daiichi Sankyo, has shown positive results in a trial of patients with advanced breast cancer.


The biopharmaceutical company says the phase III study met its primary endpoint by significantly improving (both clinically and statistically) the duration of progression-free survival in patients.

The trial's secondary endpoint, i.e. improvement in overall patient survival, was also met.

The trial, dubbed "Destiny-Breast02", compared the efficacy of Enhertu against a physician-preferred treatment of choice for HER2-positive, non-operable and/or metastatic breast cancer in patients already treated with Roche's Kadcyla.

AstraZeneca plans to present this data at an upcoming medical meeting.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.